Discovery of Evobrutinib: An Oral, Potent and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
暂无分享，去创建一个
M. Camps | A. Follis | B. Huck | A. Bender | A. Goutopoulos | R. Grenningloh | M. Meyring | A. Gardberg | I. Mochalkin | A. Wegener | Andrew T. Bender | F. Morandi | Theresa L. Johnson | B. Sherer | M. Dhanabal | S. Zimmerli | Ngan Nguyen | Hui Qiu | R. Caldwell | Christopher Jones | Justin R. Potnick | R. Schmidt | K. Urbahns | N. Brugger | B. Healey | B. Askew | A. Shutes | Brian L. Hodous | L. Liu-Bujalski | Reinaldo C Jones | Vikram Dutt | T. Eichhorn | J. Head | Dusica Santos